Clinical Trials Logo

Refractory Multiple Myeloma clinical trials

View clinical trials related to Refractory Multiple Myeloma.

Filter by:
  • Terminated  
  • Page 1 ·  Next »

NCT ID: NCT05641324 Terminated - Multiple Myeloma Clinical Trials

A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2)

Start date: February 10, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability of ANV419 monotherapy followed by ANV419 in combination with lenalidomide plus low-dose dexamethasone or ANV419 in combination with daratumumab.

NCT ID: NCT04843579 Terminated - Clinical trials for Refractory Multiple Myeloma

Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma Patients

ClaSPd
Start date: December 29, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the efficacy and safety of investigational combination therapy of Selinexor, Clarithromycin, Pomalidomide and Dexamethasone (ClaSPd) for patients with relapsed/refractory multiple myeloma. The hypothesis is that the addition of Selinexor to Clarithromycin, Pomalidomide and Dexamethasone will increase the overall response rate of patients with relapsed/refractory multiple myeloma.

NCT ID: NCT04119336 Terminated - Clinical trials for Refractory Multiple Myeloma

Nivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Myeloma

Start date: February 14, 2020
Phase: Phase 2
Study type: Interventional

This research is being done to assess the effectiveness and safety of the combination of nivolumab with ixazomib, cyclophosphamide, and dexamethasone in relapsed and refractory multiple myeloma.

NCT ID: NCT03520985 Terminated - Clinical trials for Refractory Multiple Myeloma

Alternate Day Dosing of Pomalidomide in Patients With Refractory Multiple Myeloma

OptiPOM
Start date: October 1, 2018
Phase: Phase 2
Study type: Interventional

Pomalidomide is an approved treatment for refractory multiple myeloma. Toxicity of pomalidomide in the pivotal MM-003 trial, was considerable, with 60% of patients experiencing drug-related G3/4 toxicity. Neutropenia (48% vs 16%) and pneumonia (13% vs 8%) were significantly more common in the pomalidomide arm. This resulted in frequent dose interruptions (67%) and dose reductions (27%). This suggests that for the majority of patients the 4 mg daily dosing schedule is too toxic, and that strategies to deliver reduced dosing of pomalidomide are of high practical relevance. The aim of this trial therefore is to establish that alternate day dosing of pomalidomide (4 mg q2d, d1-28) is non-inferior to daily dosing (4 mg d1-21 q28) in terms of efficacy of the drug with potentially less side effects.

NCT ID: NCT03266692 Terminated - Multiple Myeloma Clinical Trials

Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refractory Multiple Myeloma

Start date: February 22, 2018
Phase: Phase 1
Study type: Interventional

This is a phase 1, multi-center, single-arm, open-label study evaluating the safety, tolerability, and anti-myeloma activity of ACTR087 (an autologous T cell product) in combination with SEA-BCMA (a monoclonal antibody) in subjects with relapsed or refractory Multiple Myeloma.

NCT ID: NCT03201250 Terminated - Multiple Myeloma Clinical Trials

Cabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple Myeloma

Start date: February 21, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

In the currently proposed phase I/II study, the investigators aim to treat patients with relapsed and/or relapsed refractory Multiple Myeloma who have progressed on carfilzomib-based therapy with an FDA approved c-MET inhibitor, cabozantinib.

NCT ID: NCT02998047 Terminated - Clinical trials for Refractory Multiple Myeloma

A Phase I Study of Lintuzumab-Ac225 in Patients With Refractory Multiple Myeloma

Start date: December 2016
Phase: Phase 1
Study type: Interventional

1. Establish the MTD of Lintuzumab-Ac225 as monotherapy 2. Establish overall response rate (ORR) where ORR = CR + sCR+ VGPR+PR) 3. Confirm the safety profile of the treatment regimen 4. Estimate progression-free survival (PFS) and overall survival

NCT ID: NCT02020941 Terminated - Clinical trials for Refractory Multiple Myeloma

Carfilzomib in Treating Patients With Multiple Myeloma in First Relapse or Refractory to First-Line Therapy

Start date: September 2013
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well carfilzomib works in treating patients with multiple myeloma in first relapse or refractory to first-line therapy. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT01954784 Terminated - Clinical trials for Refractory Multiple Myeloma

Lenalidomide After Donor Stem Cell Transplant and Bortezomib in Treating Patients With High Risk Multiple Myeloma

Start date: October 7, 2013
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of lenalidomide after donor stem cell transplant and bortezomib in treating patients with high-risk multiple myeloma. Giving low doses of chemotherapy and total-body irradiation before a donor stem cell transplant helps stop the growth of cancer cells. It may also the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving a bortezomib at the time of transplant may stop this from happening. Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Giving lenalidomide after donor stem cell transplant may be an effective treatment for multiple myeloma.

NCT ID: NCT01676961 Terminated - Thrombocytopenia Clinical Trials

Romiplostim in Increasing Low Platelet Counts in Patients With Multiple Myeloma Receiving Chemotherapy

Start date: January 2013
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well romiplostim works in increasing low platelet counts in patients with multiple myeloma receiving chemotherapy. Romiplostim may cause the body to make platelets after chemotherapy